Exact Sciences Management

Management criteria checks 2/4

Exact Sciences' CEO is Kevin Conroy, appointed in Apr 2009, has a tenure of 15.5 years. total yearly compensation is $16.12M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth MX$974.14M. The average tenure of the management team and the board of directors is 3.8 years and 5.6 years respectively.

Key information

Kevin Conroy

Chief executive officer

US$16.1m

Total compensation

CEO salary percentage	6.5%
CEO tenure	15.5yrs
CEO ownership	0.4%
Management average tenure	3.8yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Conroy's remuneration changed compared to Exact Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$240m
Dec 31 2023	US$16m	US$1m	-US$204m
Sep 30 2023	n/a	n/a	-US$282m
Jun 30 2023	n/a	n/a	-US$432m
Mar 31 2023	n/a	n/a	-US$517m
Dec 31 2022	US$14m	US$510k	-US$624m
Sep 30 2022	n/a	n/a	-US$716m
Jun 30 2022	n/a	n/a	-US$735m
Mar 31 2022	n/a	n/a	-US$745m
Dec 31 2021	US$15m	US$963k	-US$596m
Sep 30 2021	n/a	n/a	-US$793m
Jun 30 2021	n/a	n/a	-US$829m
Mar 31 2021	n/a	n/a	-US$720m
Dec 31 2020	US$20m	US$499k	-US$824m
Sep 30 2020	n/a	n/a	-US$327m
Jun 30 2020	n/a	n/a	-US$165m
Mar 31 2020	n/a	n/a	-US$136m
Dec 31 2019	US$19m	US$792k	-US$213m
Sep 30 2019	n/a	n/a	-US$216m
Jun 30 2019	n/a	n/a	-US$221m
Mar 31 2019	n/a	n/a	-US$219m
Dec 31 2018	US$7m	US$696k	-US$175m
Sep 30 2018	n/a	n/a	-US$143m
Jun 30 2018	n/a	n/a	-US$124m
Mar 31 2018	n/a	n/a	-US$119m
Dec 31 2017	US$13m	US$633k	-US$114m

Compensation vs Market: Kevin's total compensation ($USD16.12M) is above average for companies of similar size in the MX market ($USD5.81M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.

CEO

Kevin Conroy (58 yo)

15.5yrs

Tenure

US$16,119,899

Compensation

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Conroy	Chairman of The Board & CEO	15.5yrs	US$16.12m	0.39% MX$ 974.1m
Jake Orville	Executive VP & General Manager of Pipeline	no data	US$3.67m	0.0084% MX$ 21.3m
Brian Baranick	Executive VP & General Manager of Precision Oncology	no data	US$3.57m	0.0072% MX$ 18.1m
Aaron Bloomer	Chief Financial Officer	less than a year	no data	no data
Jorge Garces	Chief Science Officer	3.5yrs	no data	no data
Nassar Nizami	Chief Information Officer	1.8yrs	no data	no data
Megan Jones	Associate Manager of Investor Relations	no data	no data	no data
Tim Caprez	Chief Compliance Counsel & VP	9.8yrs	no data	no data
James Herriott	Senior VP	2.8yrs	no data	0.0060% MX$ 15.1m
Sarah Condella	Executive Vice President of Human Resources	7.4yrs	US$2.71m	0.042% MX$ 107.2m
Graham Lidgard	Emeritus Chief Science Officer	3.8yrs	US$4.21m	no data
Ana Hooker	Chief Laboratory Officer	9.3yrs	US$3.95m	no data

3.8yrs

Average Tenure

50yo

Average Age

Experienced Management: EXAS *'s management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Conroy	Chairman of The Board & CEO	15.6yrs	US$16.12m	0.39% MX$ 974.1m
Daniel Levangie	Independent Director	14.3yrs	US$408.75k	0.015% MX$ 38.9m
D. Coward	Director	1.8yrs	US$1.47m	0.030% MX$ 75.0m
Katherine Zanotti	Independent Director	15.5yrs	US$406.25k	0.038% MX$ 95.9m
Michael Barber	Independent Director	less than a year	no data	0.0029% MX$ 7.5m
Paul Clancy	Independent Director	3.6yrs	US$417.75k	0.011% MX$ 27.6m
Kathleen Sebelius	Independent Director	5.6yrs	US$411.75k	0.017% MX$ 43.6m
Shacey Petrovic	Independent Director	4.3yrs	US$401.25k	0.012% MX$ 31.5m
James Doyle	Lead Independent Director	10.3yrs	US$442.75k	0.030% MX$ 76.0m

5.6yrs

Average Tenure

63yo

Average Age

Experienced Board: EXAS *'s board of directors are considered experienced (5.6 years average tenure).

Exact Sciences Management

Management criteria checks 2/4

Key information

Recent management updates

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Recent updates

Exact Sciences Corporation Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Exact Sciences Corporation to Report Q3, 2024 Results on Nov 05, 2024

FDA Approves Exact Sciences Corp.’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Exact Sciences Corporation(NasdaqCM:EXAS) dropped from FTSE All-World Index (USD)

Exact Sciences Presents Data Demonstrating Advancement in Blood-Based Colorectal Cancer Screening At ESMO 2024

Exact Sciences Corp. Announces First Patient Enrolled in Its Multi-Cancer Early Detection Falcon Registry Real-World Evidence Study

Second quarter 2024 earnings released: US$0.086 loss per share (vs US$0.45 loss in 2Q 2023)

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year 2024

Exact Sciences Corporation to Report Q2, 2024 Results on Jul 31, 2024

Geneoscopy, Inc. Files Counterclaims Against Exact Sciences

Geneoscopy, Inc. Files Counterclaims Against Exact Sciences

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®

First quarter 2024 earnings released: US$0.60 loss per share (vs US$0.41 loss in 1Q 2023)

Forecast breakeven date pushed back to 2026

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

Exact Sciences Corporation announced that it has received $266.75 million in funding

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation announced that it expects to receive $266.8 million in funding

Exact Sciences Corporation to Report Q1, 2024 Results on May 08, 2024

Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Exact Sciences Corporation Provides Revenue Guidance for the Year 2024

Exact Sciences Corporation to Report Q4, 2023 Results on Feb 21, 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023

Exact Sciences Corp. Announces Late-Breaking Data from the Pivotal Blue-C Trial

Exact Sciences Corporation to Report Q3, 2023 Results on Nov 01, 2023

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

New minor risk - Shareholder dilution

Forecast to breakeven in 2025

Exact Sciences Corporation Announces Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corp. Announces Positive Top-Line Results from the Pivotal Blue-C Study

Exact Sciences Corp. Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO 2023

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age